Elevation Oncology Inc

Chart & Performance

D1W1MN

P/E

—

P/S

—

EPS

—

Div Yield, %

0.00%

Shrs. gr., 5y

—

Rev. gr., 5y

Revenues

Net income

-46m

L-51.93%

CFO

-56m

L-34.28%

Profile

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

URL

https://elevationoncology.com/

IPO date

Jun 25, 2021

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12
Income
Revenues
Cost of revenue	40,377	94,576
Unusual Expense (Income)
NOPBT	(40,377)	(94,576)
NOPBT Margin
Operating Taxes	30	25
Tax Rate
NOPAT	(40,407)	(94,601)
Net income	(45,704) -51.93%	(95,080) 196.76%
Dividends
Dividend yield
Proceeds from repurchase of equity	46,479	(16)
BB yield	-253.99%	0.07%
Debt
Debt current
Long-term debt	30,137	29,435
Deferred revenue
Other long-term liabilities		2
Net debt	(52,970)	(60,845)
Cash flow
Cash from operating activities	(56,180)	(85,483)
CAPEX		(86)
Cash from investing activities	11,543	(44,398)
Cash from financing activities	47,975	29,514
FCF	(41,080)	(94,661)
Balance
Cash	83,107	90,280
Long term investments
Excess cash	83,107	90,280
Stockholders' equity	(195,957)	(56,264)
Invested Capital	280,903	134,733
ROIC
ROCE
EV
Common stock shares outstanding	34,078	23,267
Price	0.54 -43.47%	0.95 -84.22%
Market cap	18,300 -17.21%	22,104 -84.18%
EV	(34,670)	55,420
EBITDA	(40,338)	(94,549)
EV/EBITDA	0.86
Interest	4,168	479
Interest/NOPBT